EP Vantage Pharma, Biotech & Medtech 2017 in Review

Fast pace of drug and device approvals in 2017 signals wider sector health for biopharma but medtech companies struggle

Our report offers analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approvals in the pharma and medtech sectors during 2017.

Key Highlights

  • All major healthcare indices climbed in 2017, echoing wider stock market strength

  • The $80bn spent on pharma & biotech acquisitions in 2017 makes it the slowest M&A year of the past five

  • In medtech, the total value of all mergers closed in 2017 came in just shy of $100bn

Download Your Copy